INTRODUCTION: In 2024, the European Society of Cardiology (ESC) guidelines proposed a new classification of elevated blood pressure (BP) and hypertension. AIM: To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines. METHODS: In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available. RESULTS: We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001). CONCLUSION: According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.
Tocci, G., Nardoianni, G., Pala, B., Citoni, B., Virdis, A., Muiesan, M., et al. (2025). Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension. JOURNAL OF HYPERTENSION, 43(12), 2008-2015 [10.1097/hjh.0000000000004140].
Reclassification of patients with normal blood pressure levels after 2024 European society of cardiology guidelines on hypertension
Grassi, Guido;
2025
Abstract
INTRODUCTION: In 2024, the European Society of Cardiology (ESC) guidelines proposed a new classification of elevated blood pressure (BP) and hypertension. AIM: To evaluate how many individuals with optimal, normal, and high-normal BP, as defined by the 2023 European Society of Hypertension (ESH) guidelines, would be reclassified as not-elevated or elevated BP, according to the new ESC guidelines. METHODS: In this single-center, observational, retrospective, cohort study, we included adult individuals who were consecutively evaluated for home, office, and ambulatory BP measurements, and global cardiovascular risk stratification. All patients underwent BP measurements using a validated, oscillometric, automatic device (Mobil-O-Graph PWA Monitor, I.E.M. GmbH, Stolberg, Germany). Only untreated individuals with office BP levels <140/<90 mmHg and without comorbidities were considered for the analysis. Selected population was stratified according to 2023 ESH (optimal BP, <120/<80 mmHg; normal BP, 120-129/80-84 mmHg; high-normal BP, 130-139/85-89 mmHg) and then reclassified according to 2024 ESC guidelines (not-elevated BP, <120/<70 mmHg; elevated BP, 120-139/70-89 mmHg). Home and 24-h ambulatory BP levels were also evaluated in each category, when available. RESULTS: We analysed 1230 adult untreated individuals with valid office BP levels, among whom 89.0% also had ambulatory and 42.6% home BP data, respectively. According to 2023 ESH guidelines, 262 (21.3%) individuals had optimal, 375 (30.5%) normal, and 593 (48.2%) high-normal BP levels; according to 2024 ESC guidelines, 87 (7.1%) had nonelevated, and 1143 (92.9%) had elevated BP. Compared to 2023 ESH guidelines, 66.8% individuals with optimal BP, and all individuals (100.0%) with normal and high-normal BP levels were reclassified as elevated BP by adopting 2024 ESC guidelines. This shift is more evident in women than in men (67.2 vs. 65.8%; P < 0.001). CONCLUSION: According to 2024 ESC guidelines, most individuals with optimal, and all those with normal and high-normal BP levels, as defined by 2023 ESH guidelines, are reclassified in the elevated BP category.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


